drugset / Trial / NCT05480878

Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis

NCT05480878

Phase 3 Completed 90 enrolled Tanta University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims at evaluating the therapeutic effects of both Nitazoxanide and Escitalopram as adjuvant therapies in patients with Rheumatoid Arthritis and to evaluate their impact on STAT3/ JAK2, TLR /IL -1β signaling pathways.

Timeline

Start
2022-12-02
Primary completion
2023-03-25
Completion
2023-04-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 10 mg
Subject Nitazoxanide Other / unclassified 500 mg Oral
Subject Nitazoxanide Other / unclassified 1 g Oral
Subject Nitazoxanide Other / unclassified 500 g Oral

Indications